Business Wire

Theramex launches Bijuva ® / Bijuve ® (estradiol and progesterone) , the first and only body-identical combined hormone therapy treatment for post-menopausal women*

Share

PRESCRIBING INFORMATION IS AVAILABLE AT THE END OF THIS RELEASE

FOR MEDICAL BUSINESS / HEALTHCARE INDUSTRY TRADE MEDIA ONLY

Theramex has today launched Bijuva® / Bijuve® (1mg estradiol / 100mg progesterone) across Europe and the UK. Bijuva®, (known as Bijuve® in the UK), is the first, and only, body-identical hormone therapy treatment (HRT) for estrogen deficiency symptoms in post-menopausal women with intact uterus and at least 12 months since last menses, which combines estradiol and progesterone in a single daily oral capsule.1,2 Unlike synthetic hormone products, the estradiol and progesterone found in Bijuva® / Bijuve® are chemically and biologically identical to the hormones naturally circulating in the woman’s body.3

Real-world evidence, recognised by NICE and the British Menopause Society, suggests that use of body‑identical hormones is associated with lower risks compared to synthetic versions. 4,5 In particular, the evidence base demonstrates that body-identical hormones have not been shown to increase the risk of venous thromboembolism and are safer forms of HRT with respect to the risk for breast cancer, heart disease, heart attack, and stroke.6-8

The idea of using body identical hormones to replace estrogens and to protect the endometrium with progesterone appeals to many women9.These hormones that many women prefer are now available in a combined single capsule that has been shown to be effective and well-tolerated.1,9

Dr Paula Briggs, incoming Chair of the British Menopause Society, said, “We know women can be concerned about taking hormones and the impact they may have on their health beyond treating menopause symptoms. The availability of a body-identical progesterone which is well tolerated and has a lower risk profile than oral synthetic progestogens, combined with estradiol in a single capsule, is great news for women. As a healthcare community we should encourage our patients to reconsider the benefits of newer therapeutic options, allowing them to make informed choices.”

Theramex CEO, Robert Stewart, commented,For many years menopausal women and their healthcare providers have been seeking an EMA approved body-identical combination therapy. The approval of Bijuva® / Bijuve® during Menopause Awareness month represents an important new opportunity for menopausal women suffering from moderate to severe vasomotor symptoms.”

ENDS

Notes to Editor

About Bijuva® / Bijuve®

Bijuva® / Bijuve®is a fixed dose, oral, continuous combined hormonal replacement therapy (HRT) capsule containing 1mg estradiol and 100mg micronised progesterone.1 Known as Bijuve® in the UK, it is the first approved oral continuous combined body-identical estradiol–progesterone formulation in a single capsule.2 It is indicated for continuous combined HRT for estrogen deficiency symptoms in postmenopausal women with intact uterus and with at least 12 months since last menses.1 In a robust, long-term, phase III clinical trial, Bijuva® / Bijuve®demonstrated clinically relevant and statistically significant improvement in the reduction of frequency and severity of moderate-to-severe vasomotor symptoms (VMS) such as hot flushes and night sweats as early as week 3 vs placebo.9 It also demonstrated significant improvement in sleep without causing drowsiness, which delivered a significant improvement in quality of life for women taking part in the study.9 Importantly Bijuva® / Bijuve®safety was studied over 12 months of treatment, and demonstrated endometrial protection, as well as no significant changes in lipid, coagulation or glucose parameters as compared to placebo.9

The most common adverse reactions (≥3 percent) were breast tenderness, headache, vaginal bleeding, vaginal discharge and vaginal hemorrhage.9 Theramex has a license and supply agreement with TherapeuticsMD (Nasdaq: TXMD) to commercialize BIJUVA outside the United States, Canada and Israel.10

The burden of menopause

During menopause, patients may experience undesirable symptoms including vasomotor symptoms (VMS) such as hot flushes and night sweats. 11-15 In addition, women may also experience sleep deprivation, headaches, inability to concentrate, loss of memory, mood swings, vaginal dryness, loss of libido and stiffness of joints and muscles, all of which can deteriorate their quality of life. 11-15 It is estimated that vasomotor symptoms are experienced by around 75% of menopausal womenand for around a third of these women, symptoms are severe.5 Up to three-quarters of post-menopausal women experience sleep disorders, which negatively impact health-related quality of life (HRQoL) and work productivity.16,17 Menopausal symptoms can typically last around 4 years, and in around 10% of women can last up to 12 years post-menopause.4 Direct and indirect costs associated with caring for women with VMS are significantly higher than for women without VMS.16,18

About Theramex

Theramex is a leading, global speciality pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, we support women at every stage of their lives. Our commitment is to listen and understand our patients, serve their needs, and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them, by providing innovative and effective solutions that care for and support women as they advance through each stage of their lives.

References

* With intact uterus and at least 12 months since last menses

1 Theramex 2021, Summary of Product Characteristics

2 FDA Summary Review. 2018. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210132Orig1s000SumR.pdf. Accessed September 2021.

3 Kuhl H. 2005;8(Suppl 1):3-63.

4 National Institute for Health and Care Excellence. Available at https://www.nice.org.uk/guidance/ng23/. Accessed September 2021.

5 British Menopause Society. Available at https://thebms.org.uk/publications/consensus- statements/hormone-replacement-therapy/. Accessed September 2021.

6 Holtorf K. Postgrad Med. 2009;121(1):73–85.

7 Mirkin S. Climateric. 2018;21(4):346-354.

8 Fournier A, Berrine F, Clavel-Chapelon F. Breast Cancer Res Treat. 2008;107:103-111.

9 Archer DF, Bernick BA, Mirkin S. Expert Rev Clin Pharmacol. 2019;12(8):729–39.

10 Theramex. (7th June 2019). https://www.sec.gov/Archives/edgar/data/25743/000138713119004260/ex99-1.htm

11 Davis SR et al. Nat Rev Dis Primers. 2015;1: 15054. Menopause. Nat Rev 2015;1:1-19

12 Greendale GA et al. JAMA. 2020;323(15):1495-6.

13 Joffe Het al. Clin Endocrinol Metab. 2016; 101(10): 3847-55.

14 Zervas IM et al. Menopause. 2009;16(4): 837-42.

15 Jehan S et al. J Sleep Disord Ther. 2015;4(5):1-18.

16 DiBonaventura MD et al. Int J Womens Health. 2013;5:261–9.

17 Baker FC et al. Sleep Med Clin. 2018;13(3):443–56.

18 Sarrel P et al. Menopause. 2015;22(3):260–6.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andrew Bradley, Head of Communications Theramex
andrew.bradley@theramex.com / +44 (0)7864 167 962

Claire Paling, Makara Health
helenrae@makarahealth.com / +44(0)7594 225 273

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SIGNA Sports United Upsizes PIPE and Principals Agree to Backstop SPAC Business Combination With Yucaipa Acquisition Corporation18.10.2021 09:00:00 CEST | Press release

SIGNA Sports United (“SSU” or the “Company”), the world’s leading sports e-commerce and technology platform, today announced additional PIPE investments and a new redemption backstop agreement related to its proposed business combination agreement with Yucaipa Acquisition Corporation (NYSE: YAC) ("Yucaipa" or "YAC"), a publicly-traded special purpose acquisition company. These additional elements increase deal certainty and ensure the listing of the enlarged pro forma company. Mike Özkan, designated Chairman of the Board of SSU, said, “The upsizing of the PIPE demonstrates the increased interest in SSU’s sports e-commerce and technology platform. The backstop agreement underpins the principal’s commitment to the Company and provides transaction certainty for the strategic combination of the two largest online Bike retailers. The pro forma company will be in a strong position to pursue its mission to digitalize the global sports retail ecosystem with a guaranteed level of liquidity at a

BearingPoint RegTech Becomes Regnology18.10.2021 09:00:00 CEST | Press release

BearingPoint RegTech is now operating under the new name Regnology. The name stands for the company's core business: Regulatory Technology. The change of name is a logical step after BearingPoint Group sold the RegTech business to the private equity firm Nordic Capital end of 2020. Since then, the company is operationally independent. In June 2021, BearingPoint RegTech reached an important milestone by joining forces with Vizor Software, a global leader in RegTech and SupTech based in Dublin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211018005025/en/ Conor Crowley, CEO Vizor and Head of SupTech at Regnology, and Jürgen Lux, CEO, Regnology (Photo: Regnology) The combined company has a history spanning more than 20 years and is now a leading international provider of innovative regulatory, risk and supervisory technology (RegTech/RiskTech/SupTech) solutions, AEOI and tax reporting, and regulatory reporting services along

NTT: CEOs Say People and the Planet Are Becoming More Important in Business18.10.2021 08:15:00 CEST | Press release

WSJ Intelligence undertook a new international CEO survey for global technology and business solution provider NTT. The survey focuses on the role of business in contributing to societal goals. WSJ Intelligence conducted a survey of 351 CEOs of large corporations representing ten key industries in 15 countries to understand their views on their organization’s role in society, social impact strategies, the stakeholders involved, and how the Covid-19 pandemic has driven these strategies. The research confirms that post-pandemic people and the planet rather than solely profit are becoming increasingly important for organizations of all sizes. While this trend was evident before March 2020, the pandemic brought it to the forefront. The latest research considers, too, how organizations better support employee wellbeing and change management. It uncovers the most valuable tools and tips for social purpose implementation while also analyzing the most significant challenges. Key Findings: 94%

"THE GUNPLA SHOWROOM DUBAI"18.10.2021 08:00:00 CEST | Press release

BANDAI SPIRITS Co., LTD. (President and Chief Executive Officer: Nao Udagawa, Head Office: Minato-ku, Tokyo) will be operating "THE GUNPLA SHOWROOM DUBAI" from late October, 2021 to March 31, 2022, at the Dubai Mall, a shopping mall in Dubai in the city of Dubai in the United Arab Emirates, concurrently with Expo 2020 Dubai that will begin on October 1, 2021. Given the appointment of Gundam as the "PR Ambassador of the Japan Pavilion, Expo 2020 Dubai", we will be promoting Japanese culture and the joy of monodukuri (creating and crafting) to people around the world through Gunpla (Gundam-series plastic models). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211017005004/en/ Display of 1/10 scale standing Gundam statue (Photo: Business Wire) Description of "THE GUNPLA SHOWROOM DUBAI" Exhibit of 1/10 Scale Standing Gundam Statue 1/10 scale standing statue of RX-78-2 (total height: approximately 1,800 mm) will be on exhibit. Lo

Antin Infrastructure Partners to Become Majority Shareholder in Origis Energy, a Leading U.S. Renewable Energy Platform18.10.2021 07:30:00 CEST | Press release

Regulatory News: Antin Infrastructure Partners (Ticker: ANTIN – ISIN: FR0014005AL0), one of the world’s leading infrastructure investment firms, announced today that funds managed by Antin have entered into a definitive agreement to acquire a majority stake in Origis Energy, a major vertically integrated renewable energy platform in the United States, from its CEO & President Guy Vanderhaegen and Global Atlantic Financial Group. The company focuses on developing, building, and operating utility-scale solar and storage assets, as well as distributed generation. Guy Vanderhaegen will continue to lead and to hold a significant stake in the company. Founded in 2008, Origis Energy has a track record of development success across 130 solar and storage projects. Antin will support Origis Energy with additional capital and resources as it builds out its contracted pipeline, which is one of the largest in the U.S. and provides clear visibility into its growth plan over the next several years. T

Nexign Completed Campaign Management Solution for Middle East Telecom Operator Zain Kuwait18.10.2021 07:00:00 CEST | Press release

Nexign (part of ICS Holding), an international provider of business support systems (BSS), has announced that the company completed the Marketing Campaign Management system implementation for Zain Kuwait, one of the leading telecom service providers in the Middle East, in cooperation with the Turkcell Technology, a subsidiary of Turkcell, a converged telecommunication and technology services provider, founded and headquartered in Turkey. The implemented system enables Zain Kuwait to provide targeted offerings to a wide range of its subscribers and boost customer loyalty and retention. Marketing Campaign Management System is a BI-integrated solution for diversified campaigns management during the customer lifecycle. It provides selection rules management to define target segments and communication channels to schedule, execute and track the performance of marketing campaigns. The system enables the company to increase response rates and make sales and marketing initiatives more effectiv

Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL318.10.2021 07:00:00 CEST | Press release

Regulatory News: Disclaimer: Intended for international media and investor audiences only Ipsen (Euronext: IPN; ADR: IPSEY) and Accent Therapeutics (Accent) have signed an exclusive worldwide-collaboration agreement to research, develop, manufacture, and commercialize Accent’s pre-clinical stage METTL3 program. Acute myeloid leukemia (AML) is a difficult to treat cancer of the blood and bone marrow, accounting for a third of all new cases of leukemia in the US each year.1 Globally, the incidence of AML has been increasing year on year across the last 20 years.2 RNA modifying proteins (RMPs) are an emerging target class that control multiple aspects of RNA biology and represent a new approach for the potential treatment of various cancers. METTL3 is an RMP that has been validated pre-clinically as a novel therapeutic target for AML.1,3 This collaboration combines Accent’s expertise in RMP-targeting therapeutics with Ipsen’s capabilities and proven track record in Oncology medicine devel